{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Valenti L"],"funding":["Ministero della Salute","Fondazione IRCCS Ca&apos; Granda Ospedale Maggiore Policlinico","European Commission","Gilead Sciences"],"pagination":["867-877"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8948549"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(4)"],"pubmed_abstract":["The aim of this study was to examine the impact of features of dysmetabolism on liver disease severity, evolution, and clinical outcomes in a real-life cohort of patients treated with direct acting antivirals for chronic hepatitis C virus (HCV) infection. To this end, we considered 7,007 patients treated between 2014 and 2018, 65.3% with advanced fibrosis, of whom 97.7% achieved viral eradication (NAVIGATORE-Lombardia registry). In a subset (n = 748), liver stiffness measurement (LSM) was available at baseline and follow-up. Higher body mass index (BMI; odds ratio [OR] 1.06 per kg/m<sup>2</sup> , 1.03-1.09) and diabetes (OR 2.01 [1.65-2.46]) were independently associated with advanced fibrosis at baseline, whereas statin use was protective (OR 0.46 [0.35-0.60]; P < 0.0001 for all). The imp"],"journal":["Hepatology communications"],"pubmed_title":["Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study."],"pmcid":["PMC8948549"],"funding_grant_id":["Gilead Fellowship 2018 Italy","PR‐0391","RC100017A","777377","CV PREVITAL","RF‐2016‐02364358","Gilead_IN‐IT‐989‐5790","101016726"],"pubmed_authors":["Terreni N","Pelusi S","D'Ambrosio R","D'Arminio Monforte A","Zuccaro V","Colombo MC","Valenti L","Fagiuoli S","Degasperi E","Pan A","Lorini G","Buscarini E","Rumi MG","Aghemo A","Prati D","Quirino T","Bonfanti P","Lampertico P","Pasulo L","Memoli M","Spinetti A","Bianco C","Carriero C","Mendeni M","Gritti S","Re T","Iegri C","Autolitano A","Puoti M","Soria A","Cologni G","Del Poggio P","Spinelli O","Giorgini A","Aimo G","NAVIGATORE-Lombardia Network","Pigozzi MG","Vigano M","Colombo M","Carderi I","Menzaghi B"],"additional_accession":[]},"is_claimable":false,"name":"Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study.","description":"The aim of this study was to examine the impact of features of dysmetabolism on liver disease severity, evolution, and clinical outcomes in a real-life cohort of patients treated with direct acting antivirals for chronic hepatitis C virus (HCV) infection. To this end, we considered 7,007 patients treated between 2014 and 2018, 65.3% with advanced fibrosis, of whom 97.7% achieved viral eradication (NAVIGATORE-Lombardia registry). In a subset (n = 748), liver stiffness measurement (LSM) was available at baseline and follow-up. Higher body mass index (BMI; odds ratio [OR] 1.06 per kg/m<sup>2</sup> , 1.03-1.09) and diabetes (OR 2.01 [1.65-2.46]) were independently associated with advanced fibrosis at baseline, whereas statin use was protective (OR 0.46 [0.35-0.60]; P < 0.0001 for all). The imp","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-05T14:43:30.627Z","creation":"2025-04-05T14:43:30.627Z"},"accession":"S-EPMC8948549","cross_references":{"pubmed":["34811949"],"doi":["10.1002/hep4.1851"]}}